Navigation Links
Fusion gene contributes to glioblastoma progression
Date:1/9/2013

Fusion genes are common chromosomal aberrations in many cancers, and can be used as prognostic markers and drug targets in clinical practice. In this issue of the Journal of Clinical Investigation, researchers led by Matti Annala at Tampere University of Technology in Finland identified a fusion between the FGFR3 and TACC3 genes in human glioblastoma samples. The protein produced by this fusion gene promoted tumor growth and progression in a mouse model of glioblastoma, while increased expression of either of the normal genes did not alter tumor progression. Ivan Babic and Paul Mischel of the University of California, San Diego, explain in the accompanying commentary that it remains unclear how this fusion protein mediates tumorigenesis.

TITLE:
The tumorigenic fusion FGFR3-TACC3 escapes miR-99a regulation in glioblastoma

AUTHOR CONTACT:
Matti Annala
Tampere University of Technology, Tampere, , FIN
Phone: +358415079885; E-mail: matti.annala@tut.fi

View this article at: http://www.jci.org/articles/view/67144?key=b644a26bcc8a516cd41d

ACCOMPANYING COMMENTARY

TITLE:
Multiple functions of a glioblastoma fusion oncogene

AUTHOR CONTACT:
Paul Mischel
UCSD, La Jolla, CA, USA
Phone: (858) 534-6080; Fax: ; E-mail: pmischel@ucsd.edu

View this article at: http://www.jci.org/articles/view/67658?key=0186fce1cd2ddde6082f


'/>"/>

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Clearing Up the Confusion on When to Get a Pap Test
2. Big transfusions add risk for heart attack patients with anemia
3. Study: Blood transfusion associated with increased risk of death for patients with heart attack
4. Acutrack integrates with Infusionsoft ecommerce platform
5. PracticeFusion, DrFirst and Emdeon ranked as Top Electronic Prescribing Vendors Among Satisfied Clients, Black Book 2013 Survey
6. Confusion Over Diabetes Types Adds to Patients Woes
7. Complications following 2-level axial lumbar interbody fusion
8. Energy Infusion Meets Skin Care: Introducing Dahryn Silver Gel™
9. San Francisco Bath Salt Company Clears Air About Bath Salt Confusion – Zombies Beware!
10. Long-term ICS use reduces pleural effusion in patients with CAP
11. Scientists unravel role of fusion gene in prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... University of New England President Danielle ... of vice president of Student Engagement. In addition to his role as director ... life areas. , “In the space of just one year Jack has distinguished ...
(Date:4/28/2016)... ... 2016 , ... Cosmetic Town, an online plastic surgery community, announces the relaunch ... recently revamped and upgraded to allow even more interaction between doctors and patients as ... According to the senior editor of Cosmetic Town, “We are excited that our ...
(Date:4/28/2016)... ... April 28, 2016 , ... In many parts of the world, contamination ... mortality. This is particularly true in underdeveloped parts of Africa where clean sources of ... England’s campus in Tangier, Morocco, will examine this global health issue and consider how ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... of enterprise Data Center Infrastructure Management solutions, announces today the availability of ... enhancements in the area of capacity management and optimization, providing new analytical ...
(Date:4/28/2016)... ... April 28, 2016 , ... Amada Senior Care, premier provider of non-medical in-home ... – its San Antonio West location. Prior to entering the senior care industry, Amada ... opening of Amada San Antonio West will take place on Friday, April 29th. ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016  ValGenesis, Inc., ... Management Solutions (VLMS) today announced that a ... for sufferers of chronic kidney failure has ... manage their corporate validation process. The global ... software solution to manage their validation processes ...
(Date:4/27/2016)... -- Hologic, Inc. (Nasdaq: HOLX ) announced ... second quarter ended March 26, 2016.  GAAP diluted ... and non-GAAP diluted EPS of $0.47 increased 14.6%.  ... reported basis, and 6.3% on a constant currency ... quarter, highlighted by 14.6% growth in non-GAAP EPS," ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology: